As­traZeneca's Lyn­parza-Imfinzi com­bo hits pri­ma­ry end­point in PhI­II en­dome­tri­al can­cer tri­al DUO-E

As­traZeneca’s block­buster can­cer drugs Imfinzi and Lyn­parza are step­ping in­to a new in­di­ca­tion — first-line en­dome­tri­al can­cer — and sig­nif­i­cant­ly im­proved one of the dual pri­ma­ry end­points, pro­gres­sion-free sur­vival, when com­bined with chemother­a­py, the com­pa­ny an­nounced Fri­day.

De­tailed da­ta weren’t in­clud­ed in this week’s high-lev­el re­sults from the DUO-E Phase III tri­al, but As­traZeneca says an Imfinzi-chemo com­bo fol­lowed up with ei­ther Imfinzi plus Lyn­parza or Imfinzi alone as a main­te­nance ther­a­py both showed a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment com­pared to plat­inum-based chemo alone in pa­tients with new­ly-di­ag­nosed ad­vanced or re­cur­rent en­dome­tri­al can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER